These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11115068)

  • 1. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
    McCarthy KJ; Routh RE; Shaw W; Walsh K; Welbourne TC; Johnson JH
    Kidney Int; 2000 Dec; 58(6):2341-50. PubMed ID: 11115068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.
    Routh RE; Johnson JH; McCarthy KJ
    Kidney Int; 2002 Apr; 61(4):1365-76. PubMed ID: 11918743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells.
    Nicholas SB; Kawano Y; Wakino S; Collins AR; Hsueh WA
    Hypertension; 2001 Feb; 37(2 Pt 2):722-7. PubMed ID: 11230363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of type-2 diabetes and troglitazone on the expression patterns of small intestinal sugar transporters and PPAR-gamma in the Zucker diabetic fatty rat.
    Corpe C; Sreenan S; Burant C
    Digestion; 2001; 63(2):116-23. PubMed ID: 11244250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
    Okuno A; Tamemoto H; Tobe K; Ueki K; Mori Y; Iwamoto K; Umesono K; Akanuma Y; Fujiwara T; Horikoshi H; Yazaki Y; Kadowaki T
    J Clin Invest; 1998 Mar; 101(6):1354-61. PubMed ID: 9502777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular mechanisms in the development and progression of diabetic nephropathy: activation of the DAG-PKC-ERK pathway.
    Haneda M; Koya D; Kikkawa R
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S178-81. PubMed ID: 11576950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats.
    Ide T; Nakazawa T; Mochizuki T; Murakami K
    Metabolism; 2000 Apr; 49(4):521-5. PubMed ID: 10778879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats.
    Michel O; Heudes D; Lamarre I; Masurier C; Lavau M; Bariety J; Chevalier J
    Kidney Int; 1997 Dec; 52(6):1532-42. PubMed ID: 9407498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats.
    Okada M; Takemura T; Yanagida H; Yoshioka K
    Kidney Int; 2002 Jan; 61(1):113-24. PubMed ID: 11786091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats.
    Shimabukuro M; Zhou YT; Lee Y; Unger RH
    J Biol Chem; 1998 Feb; 273(6):3547-50. PubMed ID: 9452481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone.
    Sreenan S; Sturis J; Pugh W; Burant CF; Polonsky KS
    Am J Physiol; 1996 Oct; 271(4 Pt 1):E742-7. PubMed ID: 8897863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats.
    Sreenan S; Keck S; Fuller T; Cockburn B; Burant CF
    Am J Physiol; 1999 Jun; 276(6):E1119-29. PubMed ID: 10362626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.
    Isshiki K; Haneda M; Koya D; Maeda S; Sugimoto T; Kikkawa R
    Diabetes; 2000 Jun; 49(6):1022-32. PubMed ID: 10866056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats.
    Shimabukuro M; Zhou YT; Lee Y; Unger RH
    Biochem Biophys Res Commun; 1997 Aug; 237(2):359-61. PubMed ID: 9268716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonist, JTT-501, on diabetic complications in Zucker diabetic fatty rats.
    Shibata T; Takeuchi S; Yokota S; Kakimoto K; Yonemori F; Wakitani K
    Br J Pharmacol; 2000 Jun; 130(3):495-504. PubMed ID: 10821776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.
    Smith SA; Lister CA; Toseland CD; Buckingham RE
    Diabetes Obes Metab; 2000 Dec; 2(6):363-72. PubMed ID: 11225966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes.
    Shimabukuro M; Zhou YT; Levi M; Unger RH
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2498-502. PubMed ID: 9482914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
    Shibata T; Matsui K; Nagao K; Shinkai H; Yonemori F; Wakitani K
    Eur J Pharmacol; 1999 Jan; 364(2-3):211-9. PubMed ID: 9932726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effect of troglitazone on tumor necrosis factor alpha-induced expression of monocyte chemoattractant protein-1 in human mesangial cells.
    Ohta MY; Nagai Y; Takamura T; Nohara E; Kobayashi K
    Metabolism; 2000 Feb; 49(2):163-6. PubMed ID: 10690939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term cardiovascular effects of insulin sensitizer troglitazone on non-diabetic individuals with insulin resistance: double blind, prospective randomized study.
    Stakos DA; Schuster DP; Sparks EA; Wooley CF; Osei K; Boudoulas H
    J Cardiol; 2003 Apr; 41(4):183-90. PubMed ID: 12728539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.